Sarepta Therapeutics
SRPT
394 hedge funds and large institutions have $10.1B invested in Sarepta Therapeutics in 2023 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 154 increasing their positions, 125 reducing their positions, and 55 closing their positions.
24% more call options, than puts
Call options by funds: $650M | Put options by funds: $524M
23% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 125
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
8% more capital invested
Capital invested by funds: $9.38B → $10.1B (+$710M)
1.34% more ownership
Funds ownership: 87.92% → 89.27% (+1.3%)
9% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 55
2% less funds holding
Funds holding: 404 → 394 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$214M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$206M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$64.7M |
| 4 |
BlackRock
New York
|
+$59.9M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$45.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$419M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$68.1M |
| 3 |
Two Sigma Investments
New York
|
-$54.1M |
| 4 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$34.4M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$33.6M |
SRPT Hedge Fund Activity: Q3 2023 in Review
394 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2023, worth a combined $10.1B — up 7.6% from $9.38B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of SRPT and 50 opened new positions — a net loss of 5 holders — while 125 trimmed existing stakes and 154 added.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $214M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $419M sold.
- 394 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2023, down from 404 in Q2 2023.
- Funds reported $10.1B of Sarepta Therapeutics stock for Q3 2023, up 7.6% quarter-over-quarter.
- 50 funds opened new Sarepta Therapeutics positions in Q3 2023 and 55 closed out, a net change of -5 holders.
- The largest Sarepta Therapeutics buyer in Q3 2023 was T. Rowe Price Investment Management, an estimated $214M added.
- The largest Sarepta Therapeutics seller in Q3 2023 was EcoR1 Capital, an estimated $419M sold.
Based on aggregated 13F filings for Q3 2023.